News

Multinational research-based biopharmaceutical company AbbVie‘s product DUOPA is a fresh approach to the administration of carbidopa and levodopa for the treatment of motor fluctuations that afflict people with advanced Parkinson’s disease. A researcher, in an exclusive interview with Parkinson’s News Today at the recent  10th World Congress on…

That the formation of alpha-synuclein aggregates, formed by misfolded forms of the protein, is somehow linked to Parkinson’s disease development is a fact few would dispute. Whether preventing the formation, or increasing the clearance of these protein masses, possibly by vaccination, as a viable approach to treatment is, however, a…

Cynapsus Therapeutics, currently conducting a pivotal Phase 3 clinical study of its sublingual formulation of apomorphine to treat “OFF” episodes in Parkinson’s disease (PD), is teaming up with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) for a sub-study that will use wearable technology to gather and analyze…

The 10th World Congress on Controversies in Neurology (CONy), now taking place in Lisbon, Portugal, is hosting international experts in the field, and serving as a platform for the comparison of experimental clinical and basic data in a range of diseases. The congress also offers the opportunity for debate on unresolved scientific issues. Research into…

Emory University researchers, investigating the role of dopamine in the regulation of vocal learning through auditory feedback, observed that reducing this neurotransmitter in a specific brain area, the basal ganglia, considerably impairs learning. The study, in songbirds called Bengalese finches, further illuminate the role of dopamine in vocal behavior, and is relevant to Parkinson’s disease,…

For the first time, researchers have identified the point at which alpha-synuclein – the protein whose aggregation leads to Parkinson’s disease – becomes toxic. The findings, published in the journal PNAS, shed new light on the toxicity processes leading to disease development and might provide clues in the…

The 10th World Congress on Controversies in Neurology (CONy), a leading venue for researchers, clinicians, and industry leaders to discuss everything from the latest advances to unresolved issues in the field, will meet this week, March 17-20, at the Sana Lisboa Hotel in Lisbon, Portugal.

Researchers at American University in Washington, D.C. studied the rapid response that takes place in the brains of zebra finches in response to trauma and found that estrogen, produced by glial cells in the brain in response to injury, has the ability to control excessive inflammation. These findings might represent a new…

Researchers have discovered the molecular mechanisms behind calorie restriction’s neuroprotective effect in Parkinson’s disease, and propose a new therapeutic approach that uses existing drugs to reproduce the effects demonstrated in an animal model of the disease. The study by Monash University Biomedicine Discovery Institute scientists, “Ghrelin-AMPK Signaling Mediates the Neuroprotective…

Scientists have discovered a mechanism preventing Lewy bodies from forming in laboratory animals, allowing for the development of better animal models of the disease. This will likely speed up research into the disease and aid in the development of drug therapies. The main feature of the brains of Parkinson’s patients is the presence…